Literature DB >> 20610686

Evaluation of transported dry and wet cervical exfoliated samples for detection of human papillomavirus infection.

Qinghua Feng1, Stephen Cherne, Rachel L Winer, Viorica Popov, Hector Zambrano, Carlos Yerovi, Stephen E Hawes, Laura A Koutsky, Nancy B Kiviat.   

Abstract

We determined the feasibility of human papillomavirus (HPV) detection in cervical exfoliated cells collected as dry swab samples. Both dry cervical swab and specimen transport medium (STM) cervical swab samples were collected from 135 patients attending either colposcopy or women's clinics in Guayaquil, Ecuador, who had a cytology diagnosis within 6 months. HPV was detected by dot blot hybridization and genotyped by the liquid bead microarray assay (LBMA). Overall, 23.1% of dry samples were positive for any high-risk HPV types, and 24.6% of STM samples were positive for any high-risk HPV types. Of 125 paired samples, the type-specific high-risk HPV proportion positive agreement was 60.7% (kappa, 0.69; 95% confidence interval [CI], 0.53 to 0.82). Of six women with cytological evidence of invasive cervical cancer, high-risk HPV DNA was detected in three of their STM samples and in five of their dry samples. Dry samples were more likely to be insufficient for HPV testing than STM samples. Consistent with this observation, the amount of genomic DNA quantitated with the beta-actin gene was almost 20 times lower in dry samples than in STM samples when detected by the real-time TaqMan assay; however, HPV DNA viral loads in dry samples were only 1.6 times lower than those in matched STM samples. We concluded that exfoliated cervical cells could be collected as dry swab samples for HPV detection.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20610686      PMCID: PMC2937663          DOI: 10.1128/JCM.00736-10

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  17 in total

1.  Detection of high risk HPV and Chlamydia trachomatis in vaginal and cervical samples collected with flocked nylon and wrapped rayon dual swabs transported in dry tubes.

Authors:  T Krech; S Castriciano; D Jang; M Smieja; G Enders; M Chernesky
Journal:  J Virol Methods       Date:  2009-08-22       Impact factor: 2.014

2.  Comparison of three management strategies for patients with atypical squamous cells of undetermined significance: baseline results from a randomized trial.

Authors:  D Solomon; M Schiffman; R Tarone
Journal:  J Natl Cancer Inst       Date:  2001-02-21       Impact factor: 13.506

3.  The global health burden of infection-associated cancers in the year 2002.

Authors:  Donald Maxwell Parkin
Journal:  Int J Cancer       Date:  2006-06-15       Impact factor: 7.396

4.  Genital human papillomavirus infection in female university students as determined by a PCR-based method.

Authors:  H M Bauer; Y Ting; C E Greer; J C Chambers; C J Tashiro; J Chimera; A Reingold; M M Manos
Journal:  JAMA       Date:  1991 Jan 23-30       Impact factor: 56.272

5.  Use of FTA card for dry collection, transportation and storage of cervical cell specimen to detect high-risk HPV.

Authors:  Inger Gustavsson; Monica Lindell; Erik Wilander; Anders Strand; Ulf Gyllensten
Journal:  J Clin Virol       Date:  2009-07-22       Impact factor: 3.168

6.  A simple 'paper smear' method for dry collection, transport and storage of cervical cytological specimens for rapid screening of HPV infection by PCR.

Authors:  U Kailash; S Hedau; V Gopalkrishna; S Katiyar; B C DAS
Journal:  J Med Microbiol       Date:  2002-07       Impact factor: 2.472

7.  Evaluation of genital sites and sampling techniques for detection of human papillomavirus DNA in men.

Authors:  Bethany A Weaver; Qinghua Feng; King K Holmes; Nancy Kiviat; Shu-Kuang Lee; Christine Meyer; Mike Stern; Laura A Koutsky
Journal:  J Infect Dis       Date:  2004-01-29       Impact factor: 5.226

Review 8.  History of the use of HPV testing in cervical screening and in the management of abnormal cervical screening results.

Authors:  J Thomas Cox
Journal:  J Clin Virol       Date:  2009-07       Impact factor: 3.168

Review 9.  Interim guidance for the use of human papillomavirus DNA testing as an adjunct to cervical cytology for screening.

Authors:  Thomas C Wright; Mark Schiffman; Diane Solomon; J Thomas Cox; Francisco Garcia; Sue Goldie; Kenneth Hatch; Kenneth L Noller; Nancy Roach; Carolyn Runowicz; Debbie Saslow
Journal:  Obstet Gynecol       Date:  2004-02       Impact factor: 7.661

10.  Results of a randomized trial on the management of cytology interpretations of atypical squamous cells of undetermined significance.

Authors: 
Journal:  Am J Obstet Gynecol       Date:  2003-06       Impact factor: 8.661

View more
  9 in total

1.  A Randomized, Placebo-Controlled Trial of the Quadrivalent Human Papillomavirus Vaccine in Human Immunodeficiency Virus-Infected Adults Aged 27 Years or Older: AIDS Clinical Trials Group Protocol A5298.

Authors:  Timothy J Wilkin; Huichao Chen; Michelle S Cespedes; Jorge T Leon-Cruz; Catherine Godfrey; Elizabeth Y Chiao; Barbara Bastow; Jennifer Webster-Cyriaque; Qinghua Feng; Joan Dragavon; Robert W Coombs; Rachel M Presti; Alfred Saah; Ross D Cranston
Journal:  Clin Infect Dis       Date:  2018-10-15       Impact factor: 9.079

2.  High Baseline Anal Human Papillomavirus and Abnormal Anal Cytology in a Phase 3 Trial of the Quadrivalent Human Papillomavirus Vaccine in Human Immunodeficiency Virus-Infected Individuals Older Than 26 Years: ACTG 5298.

Authors:  Ross D Cranston; Michelle S Cespedes; Pawel Paczuski; Ming Yang; Robert W Coombs; Joan Dragavon; Alfred Saah; Catherine Godfrey; Jennifer Y Webster-Cyriaque; Elizabeth Y Chiao; Barbara Bastow; Timothy Wilkin
Journal:  Sex Transm Dis       Date:  2018-04       Impact factor: 2.830

3.  Rationale and design of the HOME trial: A pragmatic randomized controlled trial of home-based human papillomavirus (HPV) self-sampling for increasing cervical cancer screening uptake and effectiveness in a U.S. healthcare system.

Authors:  Rachel L Winer; Jasmin A Tiro; Diana L Miglioretti; Chris Thayer; Tara Beatty; John Lin; Hongyuan Gao; Kilian Kimbel; Diana S M Buist
Journal:  Contemp Clin Trials       Date:  2017-11-04       Impact factor: 2.226

4.  Dried cervical spots for human papillomaviruses identification.

Authors:  Valérie Charbonneau; Isabelle Garrigue; Antoine Jaquet; Apollinaire Horo; Albert Minga; Patricia Recordon-Pinson; François Dabis; Hervé Fleury
Journal:  J Med Virol       Date:  2013-04-17       Impact factor: 2.327

5.  Diagnosis of Neisseria gonorrhoeae using molecular beacon.

Authors:  Divya Sachdev; Achchhe Lal Patel; Subash Chandra Sonkar; Indu Kumari; Daman Saluja
Journal:  Biomed Res Int       Date:  2015-01-31       Impact factor: 3.411

6.  Use of swabs for dry collection of self-samples to detect human papillomavirus among Malagasy women.

Authors:  Pierre Vassilakos; Rosa Catarino; Stephanie Bougel; Maria Munoz; Caroline Benski; Ulrike Meyer-Hamme; Jeromine Jinoro; Josea Lea Heriniainasolo; Patrick Petignat
Journal:  Infect Agent Cancer       Date:  2016-03-17       Impact factor: 2.965

7.  Stability Study of Cervical Specimens Collected by Swab and Stored Dry Followed by Human Papillomavirus DNA Detection Using the cobas 4800 Test.

Authors:  Chun-Qing Lin; Xi Zeng; Jian-Feng Cui; Guang-Dong Liao; Ze-Ni Wu; Qian-Qian Gao; Xun Zhang; Xiu-Zhang Yu; Wen Chen; Ming-Rong Xi; You-Lin Qiao
Journal:  J Clin Microbiol       Date:  2016-12-07       Impact factor: 5.948

8.  Time and temperature dependent analytical stability of dry-collected Evalyn HPV self-sampling brush for cervical cancer screening.

Authors:  Ditte Møller Ejegod; Helle Pedersen; Garazi Peña Alzua; Camilla Pedersen; Jesper Bonde
Journal:  Papillomavirus Res       Date:  2018-04-22

9.  Randomized comparison of vaginal self-sampling by standard vs. dry swabs for human papillomavirus testing.

Authors:  Isabelle Eperon; Pierre Vassilakos; Isabelle Navarria; Pierre-Alain Menoud; Aude Gauthier; Jean-Claude Pache; Michel Boulvain; Sarah Untiet; Patrick Petignat
Journal:  BMC Cancer       Date:  2013-07-22       Impact factor: 4.430

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.